As of November 6, 2026, Amedisys Inc has Schedule 13D or 13G filings on record, none whose latest reports a stake of 5% or more. 4 filings are on record since August 12, 2025 (Schedule 13G/A, November 14, 2025).
Sell to companies like Amedisys Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: The Goldman Sachs Group, Inc. · Percent: 0% · SCHEDULE 13G/A
- · Holder: Pentwater Capital Management LP · Percent: 0% · SCHEDULE 13G/A
- · Holder: Pentwater Capital Management LP · Percent: 5.2% · SCHEDULE 13G
- · Holder: The Goldman Sachs Group, Inc. · Percent: 5.4% · SCHEDULE 13G
Amedisys Inc has 4 Schedule 13D or 13G filings on record since 2025-08-12. No holder's latest filing reports 5% or more. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| The Goldman Sachs Group, Inc. | 0% | 190 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Pentwater Capital Management LP | 0% | 0 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
Holding shares or following this stake? See who's behind Amedisys Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Amedisys Inc and the records around it.
Companies that share a holder
- Pentwater Capital Management LP also filed stake reports on 20 other companies: AMC Entertainment Holdings, Inc. (Aug 2026), Caesars Entertainment, Inc. (Aug 2026), Centessa Pharmaceuticals plc (Aug 2026)
- THE GOLDMAN SACHS GROUP, INC. also filed stake reports on 173 other companies: AEON ACQUISITION I CORP. (Nov 2026), ALPEX ACQUISITION CORPORATION (Nov 2026), ARCHIMEDES TECH SPAC PARTNERS II CO. (Nov 2026)
Watch Amedisys Inc
Get an email when Amedisys Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Amedisys Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Amedisys Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Amedisys Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
4 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-12 | The Goldman Sachs Group, Inc. | 5.4% | SCHEDULE 13G |
| 2025-08-14 | Pentwater Capital Management LP | 5.2% | SCHEDULE 13G |
| 2025-11-14 | The Goldman Sachs Group, Inc. | 0% | SCHEDULE 13G/A |
| 2025-11-14 | Pentwater Capital Management LP | 0% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for Amedisys Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.